Introduction: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. Discussion and conclusion: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.
|Original language||English (US)|
|Journal||European Journal of Nuclear Medicine and Molecular Imaging|
|Issue number||SUPPL. 1|
|State||Published - Mar 2008|
Bibliographical noteFunding Information:
Acknowledgements This work was supported by the National Institutes of Health grants AG22034 (JFP), P41 RR008079 (MG), and P30 NS057091 (MG), and the Minnesota Partnership for Biotechnology and Medical Genomics.
- Alzheimer's disease
- Magnetic resonance imaging
- Transgenic mouse